Moleculin Announces Proposed Underwritten Public Offering HOUSTON

Moleculin Announces Proposed

Underwritten Public Offering

HOUSTON - March 26, 2019 -

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company

with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it intends to offer and sell

units consisting of shares of common stock and warrants in an underwritten public offering. All units in the offering will be sold

by Moleculin. The proposed offering is subject to market and other conditions. There can be no assurance as to whether or when

the offering may be completed, or as to the actual size or terms of the offering.

Oppenheimer & Co. Inc. is acting

as the sole book-running manager for the proposed offering.

The Company intends to use the net

proceeds of the offering to fund its planned clinical trials, preclinical programs, for other research and development activities

and for general corporate purposes.

The securities described above are

being offered by the Company pursuant to a shelf registration statement on Form S-3 (No. 333-219434) previously filed with and

declared effective by the Securities and Exchange Commission (SEC). A preliminary prospectus supplement and the accompanying prospectus

relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website

at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained, when available,

from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004,

by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com. The final terms of the offering will be disclosed in

a final prospectus supplement to be filed with the SEC.

This press release shall not constitute

an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of

these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration

or qualification under the securities laws of any such state or jurisdiction.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage

pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly

resistant tumors. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug

resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid

leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic

transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and AML, and

WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin Biotech is also engaged in preclinical

development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of

Metabolism/Glycosylation Inhibition.

For more information about the Company, please visit http://www.moleculin.com.

Forward-Looking Statements

Some of the statements in this release

are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange

Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements

in this press release include, without limitation, statements about the anticipated completion, timing and size of the public offering

and the anticipated use of net proceeds therefrom,. Although Moleculin Biotech believes that the expectations reflected in such

forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the

results expressed or implied by such forward-looking statements as a result of various important factors, including: market conditions

that may affect the timing, terms and conditions of the offering, our ability to satisfy the conditions to closing of the offering

and other matters affecting our ability to consummate the offering on terms acceptable to us. Moleculin Biotech has attempted to

identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,''

''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words

that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions

and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors"

in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time

to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in

this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release

to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Joe Dorame, Robert Blum or Joe Diaz

Lytham Partners, LLC